U.S. Medical Devices Firm BioTek Mulls $1 Billion Sale
(Bloomberg) -- BioTek Instruments Inc., a closely held U.S. medical device maker, is exploring options including a sale amid interest from rivals and investment firms, according to people familiar with the matter.
BioTek could be valued at about $1 billion in a sale, said the people, asking not to be identified because the matter is private. Health care companies and investment funds have expressed preliminary interest in acquiring the whole company or a stake, the people said.
The Winooski, Vermont-based company's deliberations are continuing and a final decision on whether to pursue a deal hasn't been made, the people said.
"BioTek is a privately held, family owned company," Julie Bond, senior marketing operations manager with BioTek, said. "We frequently do receive inquiries from potential buyers but it's our policy not to comment on any market rumors."
Founded in 1968, BioTek makes cell-imaging systems, test-tube plate readers, incubators and other instruments and software for life sciences research and drug discovery, according to its website. Last year, it announced that it would collaborate with Agilent Technologies Inc. to provide a new kind of cellular analysis system.
About $30.7 billion in deals involving health-care products companies have been announced so far this year, an increase of almost 30 percent from the same period in 2018, according to data compiled by Bloomberg. That includes General Electric Co.'s agreement to sell its biopharma business to Danaher Corp. for $21.4 billion and Johnson & Johnson's $3.4 billion acquisition of surgical robotics company Auris Health Inc.
--With assistance from Rebecca Spalding.
To contact the reporters on this story: Manuel Baigorri in Hong Kong at mbaigorri@bloomberg.net;Kiel Porter in Chicago at kporter17@bloomberg.net
To contact the editors responsible for this story: Fion Li at fli59@bloomberg.net, ;Elizabeth Fournier at efournier5@bloomberg.net, Matthew Monks, Michael Hytha
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.